Psoriatic arthritis (PsA) is a chronic form of arthropathy commonly associated with psoriasis. Patients are evaluated on five disease domains: peripheral arthritis, axial disease, enthesitis, dactylitis, and nail and skin involvement. Due to the heterogeneity of clinical symptoms, PsA can be difficult to diagnose and treat.
Current therapies for disease management include conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), injectable immuno-suppressants and oral small molecule therapies. Of these, intravenous and subcutaneous therapies targeting tumor necrosis factor (anti-TNFs) have been the gold standard of care for almost 20 years. However, other mechanisms of action have gained traction in recent years. Over the forecast period, market growth is expected to be driven primarily by the approval and launch of five pipeline therapies. However, this growth will likely be curtailed by the erosion of branded agents sales by biosimilars and generics in the second half of the forecast period.
KEY QUESTIONS ANSWERED
Which unmet needs are limiting the treatment of PsA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)?
What strategies can the pharmaceutical industry employ to increase treatment rates for PsA? How should these strategies differ across different geographical markets?
What effect will the launch of biosimilars and generics have on the sales of branded agents? What can drug manufacturers do in order to ensure the success of their biosimilars?
What are the main R&D trends in the PsA market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in late-stage versus early-stage clinical development?
Overview of PsA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline PsA market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsA therapeutics sales in the 7MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global PsA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The greatest drivers of growth in the global PsA market include the launch of five new pipeline therapies during the forecast period and a steadily climbing diagnosed prevalence in many 7MM countries.
The main barriers to growth in the PsA market include low diagnostic and treatment rates as well as low patient compliance and persistence.
Among the late-stage pipeline products, two are injectable anti-interleukin therapies and three are oral Janus Kinase (JAK) inhibitors.
The most important unmet needs in the PsA market are increased access to therapies as well as therapies that can target the multiple disease domains.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global PsA therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsA market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global PsA therapeutics market from 2018-2028.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Johnson & Johnson (J&J)
Kyowa Hakko Kirin
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Psoriatic Arthritis: Executive Summary
2.1 PsA Market to Experience Moderate Growth from 2018–2028
2.2 Oral Therapeutics Dominate the Late-Stage PsA Pipeline
2.3 Opportunities Remain for More Cost-Effective and Targeted Treatments
2.4 Convenient and Affordable Pipeline Agents Poised to Perform Well in a Crowded PsA Market
2.5 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Sources Not Used
5.5 Epidemiological Forecast for Psoriatic Arthritis (2018-2028)
5.5.1 Diagnosed Incident Cases of PsA
5.5.2 Diagnosed Prevalent Cases of PsA
5.5.3 Sex-Specific Diagnosed Prevalent Cases of PsA
5.5.4 Age-Specific Diagnosed Prevalent Cases of PsA
5.5.5 Diagnosed Prevalent Cases of PsA by Severity
5.5.6 Diagnosed Prevalent Cases of PsA with Psoriasis
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Diagnostic Scales
6.1.2 Treatment Guidelines by Market
7 Competitive Assessment
7.1.1 TNF Inhibitors
7.1.2 IL-17 Inhibitors
7.1.3 IL-23 Inhibitors
7.1.4 Janus Kinase Inhibitors
7.1.5 Other Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs
8 Unmet Needs and Opportunity Assessment
8.2 Increased Clinician Awareness of PsA
8.3 Earlier and More Accurate PsA Diagnoses
8.4 Improved Drug Safety and Efficacy Across All Disease Domains
8.5 Improved Access to Therapies
9 Pipeline Assessment
9.1.1 IL-17 Inhibitors
9.1.2 IL-23 Inhibitors
9.1.3 JAK Inhibitors
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development
10 Current and Future Players
10.2 Trends in Corporate Strategy
10.5 Johnson & Johnson
10.6 Bristol-Myers Squibb
10.10 Eli Lilly
10.12 Sun Pharma
10.13 Kyowa Hakko Kirin
11 Market Outlook
11.1 Global Markets
11.1.2 Drivers and Barriers – Global Issues
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4.2 Key Events
11.4.3 Drivers and Barriers
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research – KOLs and Payers Interviewed for This Report
12.5 Primary Research – Prescriber Survey
12.6 About the Authors
12.6.2 Therapy Area Director
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
List of Tables
Table 1: Psoriatic Arthritis: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbidities for PsA
Table 3: Classification Systems in PsA
Table 4: Treatment Guidelines for PsA by Market
Table 5: Country Profile – US
Table 6: Country Profile – 5EU
Table 7: Country Profile – Japan
Table 8: Leading Treatments for Psoriatic Arthritis, 2019
Table 9: Marketed Biosimilars for PsA, 2019
Table 10: 7MM, Non-Responsive Patients by Drug Class, All Severities, 2019
Table 11: AbbVie’s Disease Portfolio Assessment, 2020
Table 12: Pfizer’s Disease Portfolio Assessment, 2020
Table 13: J&J’s Disease Portfolio Assessment, 2020
Table 14: Bristol-Myer’s Squibb Disease Portfolio Assessment, 2020
Table 15: UCB’s Disease Portfolio Assessment, 2020
Table 16: Amgen’s Disease Portfolio Assessment, 2020
Table 17: Novartis’ Disease Portfolio Assessment, 2020
Table 18: Eli Lilly’s Disease Portfolio Assessment, 2020
Table 19: Gilead Disease Portfolio Assessment, 2020
Table 20: SunPharma’s Disease Portfolio Assessment, 2020
Table 21: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2020
Table 22: PsA Market – Global Drivers and Barriers, 2018–2028
Table 23: Key Events Impacting Sales for PsA in the US, 2018–2028
Table 24: PsA Market – Drivers and Barriers in the US, 2018–2028
Table 25: Key Events Impacting Sales for PsA in the 5EU, 2018–2028
Table 26: PsA Market – Drivers and Barriers in the 5EU, 2018–2028
Table 27: Key Events Impacting Sales for PsA in Japan, 2018–2028
Table 28: Psoriatic Arthritis Market – Global Drivers and Barriers in Japan, 2018–2028
Table 29: Key Historical and Projected Launch Dates for PsA
Table 30: Key Projected Patent Expiry Dates for PsA
Table 31: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for PsA in 2018 and 2028
Figure 2: Analysis of the Company Portfolio Gap in PsA During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents for PsA, 2020
Figure 4: Key Molecular Targets in Psoriatic Arthritis
Figure 5: 7MM, Diagnosed Prevalence of PsA, Men and Women, Ages ≥18 Years, 2008
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of PsA
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PsA
Figure 8: 7MM, Diagnosed Incident Cases of PsA, Men and Women, Ages ≥18 Years
Figure 9: 7MM, Diagnosed Prevalent Cases of PsA, Men and Women, Ages ≥18 Years
Figure 10: 7MM, Diagnosed Prevalent Cases of PsA by Sex, Ages ≥18 Years, 2018
Figure 11: 7MM, Diagnosed Prevalent Cases of PsA by Age, Men and Women, 2018
Figure 12: 7MM, Diagnosed Prevalent Cases of PsA by Severity, Men and Women, Ages ≥18 Years, 2018
Figure 13: 7MM, Diagnosed Prevalent Cases of PsA with Psoriasis, Men and Women, Ages ≥18 Years
Figure 14: EULAR Treatment Algorithm for Psoriatic Arthritis, 2015
Figure 15: GRAPPA Treatment Algorithm for Psoriatic Arthritis
Figure 16: Unmet Needs and Opportunities in PsA, 2019
Figure 17: Overview of the Development Pipeline in Psoriatic Arthritis
Figure 18: Key Phase II/III Trials for the Promising PsA Pipeline Agents
Figure 19: Competitive Assessment of the Late-Stage Pipeline Agents for PsA, 2020
Figure 20: Analysis of the Company Portfolio Gap in PsA During the Forecast Period
Figure 21: Global (7MM) Sales Forecast by Country for PsA in 2018 and 2028
Figure 22: Sales Forecast for PsA in the US, by Class, 2018 and 2028
Figure 23: Sales Forecast for PsA in the 5EU, by Class, 2018 and 2028
Figure 24: Sales Forecast for PsA in Japan, by Class, 2018 and 2028